WINDTREE THERAPEUTICS INC (WINT) Stock News
NASDAQ:WINT - Nasdaq - US97382D5014 - Common Stock - Currency: USD
WINT Latest News and Analysis
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline
The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidate...
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value...
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company...
Sidoti Events, LLC's Virtual November Micro-Cap Conference
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong
Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure...
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree To Present at the ThinkEquity Conference on October 30th
WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients with early cardiogenic...
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or...
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including...
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many...
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024
Windtree Therapeutics just reported results for the first quarter of 2024.
WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Windtree Therapeutics (NASDAQ:WINT) just reported results for the first quarter...
Windtree Announces New Additions and Changes to Its Board of Directors
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
